Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.
about
Polyphasic characterization reveals that the human pathogen Mycobacterium peregrinum type II belongs to the bovine pathogen species Mycobacterium senegalense.Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteriaManagement of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic SocietyIn vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobialsCorrelation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteriaCloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutationsAntimicrobial susceptibility of standard strains of nontuberculous mycobacteria by microplate Alamar Blue assayNon-tuberculous mycobacterial tenosynovitis: a review.Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum.Clinical and laboratory features of Mycobacterium mageritense.Activities of linezolid against rapidly growing mycobacteria.Infection of the subcutis and skin of cats with rapidly growing mycobacteria: a review of microbiological and clinical findings.High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan.Management of bacterial keratitis: beyond exorcism towards consideration of organism and host factors.Therapy of nontuberculous mycobacterial infections.Activities of moxifloxacin in combination with macrolides against clinical isolates of Mycobacterium abscessus and Mycobacterium massiliense.Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea.Clinical significance, biochemical features, and susceptibility patterns of sporadic isolates of the Mycobacterium chelonae-like organism.Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testingNewly documented antimicrobial activity of quinolones.A review of the antimicrobial activity of the fluoroquinolones.Sequence-based identification of Mycobacterium species using the MicroSeq 500 16S rDNA bacterial identification system.Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.Sequences of conserved region in the A subunit of DNA gyrase from nine species of the genus Mycobacterium: phylogenetic analysis and implication for intrinsic susceptibility to quinolones.In vitro susceptibilities of rapidly growing mycobacteria to newer antimicrobial agents.Recent changes in taxonomy and disease manifestations of the rapidly growing mycobacteria.The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children?Cardiac device infections due to Mycobacterium fortuitum.Mycobacterium tuberculosis pyomyositis in an infant.Antimycobacterial activity of DNA intercalator inhibitors of Mycobacterium tuberculosis primase DnaG.In vitro antibiotic susceptibility of rapidly growing nontuberculous mycobacteria isolated from patients with microbial keratitis.Levofloxacin alone efficiently treated a cutaneous mycobacterium fortuitum infection.Mycobacterium fortuitum: an iatrogenic cause of soft tissue infection in surgery.Generation of resistant mutants of Mycobacterium chelonae and Mycobacterium fortuitum after exposure to subinhibitory concentrations of clarithromycin and moxifloxacin.
P2860
Q24535187-DE88CA2C-A54E-42D9-9E70-9015B762CE51Q24535651-C8656290-E981-4DEE-ADC6-0F6CB7B51935Q24679338-BD09451A-368C-494D-854A-265BBB9A9E37Q28343826-49499E07-FC6B-43E6-9FCA-FBB77021EFE1Q28368322-25770698-824B-4749-B2C3-C92078F740D4Q28369291-EA533BC4-AE3D-4D16-AD74-09BADBB9B81DQ28538099-13BD25FE-9133-426A-810A-F024E1E37AB7Q33730779-FFE66502-00F9-4496-8EA1-9D618A0B8DB0Q33960674-9638DFD6-971D-49AD-89DB-C435A45AF677Q33965927-B20F047B-DF2D-4300-9F38-53439E231BDCQ33981613-EC542C38-DBE5-420D-A2E8-F4BA948A216BQ34444654-FE104B1D-01BC-4961-8896-48517432FE5CQ35014132-9D482AD1-F38A-437B-9D68-B5E31A3A090BQ35590415-83465DA3-D92B-4AFA-AC00-84D408701297Q35967427-B2437590-5336-4270-8CE3-FE176D551883Q36086312-CEBEF20D-A78A-4D06-8B81-C1D3603FA752Q36156072-CA39B1E1-4C7C-4B36-8930-A16884E1309DQ36854356-23CE6C84-B80E-48CC-9B2E-6A26F5F75CCFQ37146435-DD51F609-8FC1-4C74-9C65-DBB51B9DE42EQ37221170-E1996B24-F57A-4FA2-B324-CECE1D49764CQ37222571-B573AC68-18AF-4CFC-8A47-2FFF9A9812B1Q37834318-E1DEEB92-8D18-4878-B4CD-E1766DDD05BFQ39468032-1F963BC2-7C21-42E4-AC55-BD976E8B55D0Q39658153-1C689D88-A790-41C4-8473-24368E137712Q39780515-8E784F9E-23F6-451E-A35D-0FBF190A70FDQ40284828-6CEEEDF5-341A-488F-8994-967E018D189AQ40494955-14C71069-C9CE-499F-9E64-C9DABDE5899CQ40636919-E955B124-2D8F-4030-905B-103C46696551Q40670499-C34385FC-663A-4085-A32E-3F3E38ED4BF1Q41828834-5E64801E-F66E-4454-AA00-7D07D6E98D91Q42186282-7050DB0B-44FA-428A-B1C2-83D2D9F830F8Q43107310-D82D60BD-B8D3-423C-8426-D9F46498BEF8Q44107001-6A9DED71-6599-427C-918F-09C89ED98CE3Q45021417-7C70E870-D3A2-44CB-A4FC-80AA5DF24DB7Q46855573-3FB314B6-C8EC-4434-A7D8-78EA07A3A736
P2860
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Activities of ciprofloxacin an ...... following single-drug therapy.
@ast
Activities of ciprofloxacin an ...... following single-drug therapy.
@en
type
label
Activities of ciprofloxacin an ...... following single-drug therapy.
@ast
Activities of ciprofloxacin an ...... following single-drug therapy.
@en
prefLabel
Activities of ciprofloxacin an ...... following single-drug therapy.
@ast
Activities of ciprofloxacin an ...... following single-drug therapy.
@en
P2093
P2860
P356
P1476
Activities of ciprofloxacin an ...... following single-drug therapy.
@en
P2093
Sanders CV
Wallace RJ Jr
P2860
P356
10.1128/AAC.34.1.65
P407
P577
1990-01-01T00:00:00Z